Company intelligence / Profile preview
Pharmicell Co., Ltd.
- Ownership
- Private
- Development stage
- Commercial
Overview
Pharmicell developed the world's first stem cell therapy (Hearticellgram-AMI) approved in 2011. They have multiple programs in clinical trials, including treatments for liver cirrhosis and erectile dysfunction.
- Therapeutic areas
- GastroenterologyOncologyCardiovascularMen's Health
- Modalities
- Stem Cell TherapyDendritic Cell TherapyPharmaceutical Intermediates
- Industry
- Biotech
Drug pipeline
10 assets9 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Pharmicell Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pharmicell Co., Ltd..